// App-Quantinova.ai

: DNA-Based Digital PCR for the Quantification of Residual Disease in CML — Sensitivity or Specificity?

Researchers

Presenter

  • Mary Alikian

Principal Investigators

  • Rebecca Ellwood

  • Olga Tatarinova

  • Graham David Rose

  • George Nteliopoulos

  • Gareth Gerrard

  • Jamshid S Khorashad

  • Dragana Milojkovic

  • Alistair Reid

  • Letizia Foroni

  • Richard Clark

  • Jane Apperley

Medical Centers

  • Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom

  • Paediatric Haematology, Imperial College Healthcare NHS Trust, London,United Kingdom

  • Paediatric Haematology, Imperial College Healthcare NHS Trust, London,United Kingdom

  • UCL Cancer Institute, University College London,, London, United Kingdom

  • Paediatric Haematology, Imperial College Healthcare NHS Trust, London,United Kingdom

  • Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom

  • Molecular Pathology Unit, Royal Liverpool University Hospital, Liverpool University, Liverpool, United Kingdom

  • Royal Liverpool University Hospitals NHS Trust, Liverpool, GBR

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Nilotinib

  • dasatinib

  • Imatinib

  • IkT001

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved